Skip to main content
Clinical Trials/EUCTR2010-020219-35-DE
EUCTR2010-020219-35-DE
Active, not recruiting
Not Applicable

Evaluating the benefit of additional platelet inhibition in acute coronary syndrome patients with high platelet reactivity undergoing PCI - APACS-HPR

Royal Brompton & Harefield NHS Foundation Trust0 sites140 target enrollmentApril 5, 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Royal Brompton & Harefield NHS Foundation Trust
Enrollment
140
Status
Active, not recruiting
Last Updated
12 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 5, 2011
End Date
TBD
Last Updated
12 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • PATIENT INCLUSION CRITERIA REGISTRY
  • a) ACS patients with intent for PCI \<72 hours from admission.
  • b) Prior clopidogrel loading within 24h before planned PCI or chronic (\>24 hours) treatment with clopidogrel
  • c) Low platelet reactivity (HPR) PA \<400 AU min by multiplate analyser (good responders”). Blood sample to be taken
  • at least 2 hrs after prior clopidogrel loading.
  • d) Consent.
  • PATIENT INCLUSION CRITERIA FOR RANDOMISED APACS STUDY
  • a) ACS patients with intent for PCI \<72 hours from admission.
  • b) Prior clopidogrel loading within 24h before planned PCI or chronic (\>24 hours) treatment with clopidogrel.
  • c) High platelet reactivity (HPR) PA \=400 AU min by multiplate analyser (poor responders”).

Exclusion Criteria

  • PATIENT EXCLUSION CRITERIA RANDOMISED APACS STUDY
  • a) Patients \<18 years and \=75 years
  • b) Body weight \<60kg
  • c) Pretreatment with prasugrel within 7 days of randomisation
  • d) History of stroke or transient ischaemic attack
  • e) Patients with increased bleeding risk e.g.
  • recent major trauma or surgery
  • gastrointestinal bleeding or active peptic ulceration
  • Platelet count \<100,000 / mm3 at the time of screening
  • Internationally Normalized Ratio (INR)\> 1\.5 at the time of screening

Outcomes

Primary Outcomes

Not specified

Similar Trials